Lung scan-guided radiation planning for adults with lung cancer
Tests a lung scan to spare working lung tissue during radiation.
Plain-language title generated from the registry record
Registry title: Functional Lung Avoidance SPECT-guided Radiation Therapy of Lung Cancer
Key facts
- Where
- Aarhus, DenmarkSee the site
Where in Denmark
- Department of Oncology, Aarhus University HospitalAarhus, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Aarhus
- Trial code
- NCT04676828
- Record updated
- 24 February 2026
- Original description
Study aims to determine if functional lung avoidance based on perfusion single photon emission (SPECT)/CT scan, improves toxicity outcomes for patients with advanced lung cancer undergoing chemo-radiotherapy. Functional avoidance implies a dose plan that takes functional distribution in the lung into account, and avoids highly functional lung volumes sparing them from radiation.Read full original descriptionShow less
Functional Lung Avoidance SPECT-guided (ASPECT) Radiation Therapy for Lung Cancer Patients: Phase II Randomised Clinical Trial
Study aims to determine if functional lung avoidance based on perfusion single photon emission (SPECT)/CT scan, improves toxicity outcomes for patients with advanced lung cancer undergoing chemo-radiotherapy. Functional avoidance implies a dose plan that takes functional distribution in the lung into account, and avoids highly functional lung volumes sparing them from radiation.
Inclusion: histologically verified lung cancer (small-cell and non-small cell lung cancer); referred for radiotherapy with curative intent; radiation dose of 60-66 Gy given in 2-Gy fractions, other dose levels and fractionation schedules accepted, as per site standard; concurrent chemotherapy is accepted; patients with oligometastatic disease are allowed, where metastasis have been ablated with surgery or radiotherapy; receiving (chemo)-radiotherapy to the thoracic disease with curative intent; adults over 18, that have given oral and written informed consent before patient registration.
Exclusion: concurrent immunotherapy; previous radiotherapy to the thorax; other uncontrolled malignancies; any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol.